RoosterBio Inc, a Frederick Maryland Biotech Startup, Achieves Rapid Traction with Product Launch and Fundraising Milestone
RoosterBio Inc is a new biotech start-up supplying human bone marrow-derived Mesenchymal Stem Cells (hBM-MSC) for tissue engineering research and stem cell-based product development into the high growth Synthetic Biology and Regenerative Medicine fields.
Frederick, MD (PRWEB) February 25, 2014
RoosterBio Inc is a new biotech start-up supplying human bone marrow-derived Mesenchymal Stem Cells (hBM-MSC) for tissue engineering research and stem cell-based product development into the high growth Synthetic Biology and Regenerative Medicine fields. RoosterBio, Inc. initiated laboratory operations in October, 2013, and has achieved the critical milestone of first product shipment to paying customers in just four short months. In addition to the early validation of their business model and rapidly generating revenue, Roosterbio has raised over 250K in seed investment and are actively seeking funds via AngelList (https://angel.co/roosterbio).
RoosterBio credits their quick-to-market accomplishments to hyper-efficient operations and the passion that the RoosterBio team shares in their desire to assist tissue engineers and cell therapists to accelerate life-saving technologies into the clinic. “Our laser focus coupled with operational excellence has enabled us to reach these milestones; we will delight our customers with our product offering”, says Chief Operating Officer, Dr. Uplaksh Kumar. The RoosterBio team’s extensive experience sourcing raw materials, manufacturing stem cell products, and controlling for high quality with best-in-class characterization techniques has allowed them to successfully launch their flagship hBM-MSC product quickly and efficiently.
Dr. Jon Rowley, RoosterBio’s Chief Executive said “I can’t express how proud I am of our small, highly dedicated team that worked tirelessly to get our first products designed, manufactured, quality tested, released, and just as importantly sold and shipped to our first paying customers. This was truly a team effort that couldn’t have been done without each and every person at RoosterBio.”
Having spent years as cell and tissue technologists, the RoosterBio team has an intimate understanding of the pain points surrounding the generation of large numbers of robust, reproducible, standardized cells for research and product development purposes. RoosterBio products are designed to solve this problem and they believe that high volume and affordable cellular raw materials will kick-start the cell-based medical product revolution.
Dr. Sarah Griffiths, a Researcher at Georgia Tech in Atlanta, believes that RoosterBio’s MSCs will do exactly that, and was anxiously awaiting receipt of the product. "We are excited to receive the first shipment of RoosterBio’s product. The potential to generate large stocks of MSCs in a short period of time will be a tremendous advantage to the progress of our research."
Researchers in the fields of Synthetic Biology and Regenerative Medicine, such as Dr. Griffiths, will use RoosterBio’s MSC’s to develop new medical therapies to provide treatments for degenerative diseases such as Parkinson’s and Alzheimer’s diseases, or to repair or replace tissue after a catastrophic injury such as traumatic bone and cartilage injury, spinal cord damage, heart attack, or significant burns.
RoosterBio’s current focus is to supply high volume research-grade cells manufactured with processes consistent with current Good Manufacturing Practices (cGMP). They are rapidly approaching their next milestones by laying the groundwork for initiating production of clinical-grade cells to be used in translational R&D and clinical studies.
RoosterBio is focused on building a robust and sustainable Regenerative Medicine industry. Our products are affordable and standardized primary cells and media, manufactured and delivered with highest quality and in formats that simplify product development efforts. RoosterBio products are made with care in Frederick, MD, and will accelerate the translation of cell therapy and tissue engineering technologies into the clinic.
For the original version on PRWeb visit: http://www.prweb.com/releases/2014/02/prweb11603096.htm